FOX04

FOXO4-DRI (also known as Proxofim) is a synthetic peptide with a retro-inverso structure, developed by Dutch researchers as a modified version of the FOXO4 protein with an extended half-life. Its primary function is to disrupt the interaction between FOXO4 and the tumor suppressor protein p53, leading to the selective apoptosis of senescent cells and a deceleration of biological aging. Studies have demonstrated that FOXO4-DRI modulates multiple regulatory pathways, including insulin signaling, cell cycle control, and oxidative stress response. It also shows potential in eliminating the pro-inflammatory phenotype of senescent cells and improving the functional microenvironment of tissues.